Exit

Huma has bought Surrey-founded wellness tracking app developer Biobeats to increase the number of digital biomarkers that underpin its services.

Invesco will sell its unquoted UK holdings to reallocate its capital to public stocks, meaning disruption for numerous spinouts and Oxford Sciences Innovation.

Niantic has purchased University of Oxford’s augmented reality engine developer 6D.ai and will use the spinout’s technology for large-scale mapping for its games.

Underwriters have exercised their over-allotment option in full, increasing the University of Pennsylvania-linked genetic medicine developer’s proceeds by $32.4m.

Electric skateboard producer Boosted, backed by Stanford-StartX Fund, has laid off employees after its business model succumbed amid the US-China tariff war.

The UC Santa Barbara-founded semiconductor technology producer has gone public through a reverse merger with penny stock company Peninsula Acquisition and received $21.5m from investors including Marelli.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.